Skip to main content
. Author manuscript; available in PMC: 2023 Aug 9.
Published in final edited form as: Sci Transl Med. 2021 Sep 1;13(609):eabe6805. doi: 10.1126/scitranslmed.abe6805

Fig. 6. LRG1 neutralization delays metastatic progression and prolongs overall survival.

Fig. 6

(A) Therapeutic assessment of LRG1-blocking antibody 15C4 in LLC and MMTV-PyMT murine metastasis models using a postsurgical adjuvant strategy. (B) For the LLC tumor model, Kaplan-Meier graphs showing overall survival of mice when treated with control-IgG or anti-LRG1 (15C4) antibody in the postsurgical adjuvant (B; n = 8-9 mice) setting. **, P<0.01 [Log-rank (Mantel-Cox) test]. (C) For the MMTV-PyMT tumor model, Kaplan-Meier graph showing overall survival of mice when treated with control-IgG or anti-LRG1 (15C4) antibody in the postsurgical adjuvant setting (n = 9-11 mice). Mice were treated from day 1 until day 60 post-primary tumor resection with IgG or anti-LRG1 (15C4) antibody. 3 of 11 15C4-treated and 1 of 9 control-IgG-treated mice were healthy until the end of experiment. *, P<0.05 [Log-rank (Mantel-Cox) test]. For moribund mice (n = 8-9 for the LLC model and n = 8 per treatment group for the MMTV-PyMT model), fig. S14C shows the incidence of lung metastases.